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Lrp5 and Lrp6 Exert Overlapping Functions in
Osteoblasts during Postnatal Bone Acquisition
Ryan C. Riddle1,2*, Cassandra R. Diegel3, Julie M. Leslie1, Kyle K. Van Koevering3, Marie-Claude Faugere4,
Thomas L. Clemens1,2, Bart O. Williams3*
1 Department of Orthopaedic Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America, 2 Veterans Administration Medical
Center, Baltimore, Maryland, United States of America, 3 Center for Skeletal Disease and Tumor Metastasis and Laboratory of Cell Signaling and Carcinogenesis, Van Andel
Research Institute, Grand Rapids, Michigan, United States of America, 4 Department of Medicine, University of Kentucky, Lexington, Kentucky, United States of America

Abstract
The canonical Wnt signaling pathway is critical for skeletal development and maintenance, but the precise roles of the
individual Wnt co-receptors, Lrp5 and Lrp6, that enable Wnt signals to be transmitted in osteoblasts remain controversial. In
these studies, we used Cre-loxP recombination, in which Cre-expression is driven by the human osteocalcin promoter, to
determine the individual contributions of Lrp5 and Lrp6 in postnatal bone acquisition and osteoblast function. Mice
selectively lacking either Lrp5 or Lrp6 in mature osteoblasts were born at the expected Mendelian frequency but
demonstrated significant reductions in whole-body bone mineral density. Bone architecture measured by microCT revealed
that Lrp6 mutant mice failed to accumulate normal amounts of trabecular bone. By contrast, Lrp5 mutants had normal
trabecular bone volume at 8 weeks of age, but with age, these mice also exhibited trabecular bone loss. Both mutants also
exhibited significant alterations in cortical bone structure. In vitro differentiation was impaired in both Lrp5 and Lrp6 null
osteoblasts as indexed by alkaline phosphatase and Alizarin red staining, but the defect was more pronounced in Lrp6
mutant cells. Mice lacking both Wnt co-receptors developed severe osteopenia similar to that observed previously in mice
lacking b-catenin in osteoblasts. Likewise, calvarial cells doubly deficient for Lrp5 and Lrp6 failed to form osteoblasts when
cultured in osteogenic media, but instead attained a chondrocyte-like phenotype. These results indicate that expression of
both Lrp5 and Lrp6 are required within mature osteoblasts for normal postnatal bone development.
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and homozygosity for a germline inactivating allele results in
neonatal lethality, suggesting that this co-receptor plays a
dominant role in early development [9]. The expression pattern
of Lrp5 is more restricted [5,10,11].
All components of the canonical Wnt signaling pathway,
including Lrp5 and Lrp6, are expressed by the osteoblast [12–
14], and have been firmly linked with bone development and
maintenance in mice and humans. The importance of LRP5 in
bone was initially established by demonstrating that inactivating
mutations in this co-receptor caused osteoporosis pseudoglioma
(OPPG), a rare syndrome associated with premature and
generalized osteoporosis [13]. Subsequently, patients carrying a
point mutation in LRP5 (G171V) that increases Wnt signaling
capacity were shown to exhibit strikingly high bone mass [15,16].
Individuals with mutations in LRP6 also develop osteoporosis and
display other abnormalities including diabetes, hypertension, and
early-onset cardiovascular disease associated with high levels of
LDL and triglycerides [17].
While the importance of canonical Wnt signaling in skeletal
development is well documented [18,19], the sequence of
molecular events that activate this pathway both up- and

Introduction
The canonical Wnt signaling pathway is a key regulator of the
development of many tissues, but the specific biological roles of the
Wnt co-receptors low-density lipoprotein receptor-related protein
5 (Lrp5) and Lrp6 in the skeleton remain controversial. Wnt
ligands bind to a receptor complex containing a member of the
Frizzled family of receptors and either Lrp5 or Lrp6. These cell
surface events trigger a cascade of intracellular reactions that
facilitate nuclear import of b-catenin, which then interacts with the
Lef/Tcf class of DNA binding proteins to regulate target gene
expression [1,2].
Lrp5 and Lrp6 are 71% homologous and form a distinct
subfamily of the LDL receptor-related proteins [3–5]. Both coreceptors have four YWTD-b-propeller domains that are followed
by EGF-like domains and allow binding to extracellular ligands,
and five intracellular PPP(S/T)P domains that mediate downstream signaling events [1]. Previous studies have suggested that
Lrp5 and Lrp6 mediate distinct actions owing to differences in
tissue distribution and affinity for individual Wnt ligands [6–8].
For example, in the developing embryo Lrp6 is widely expressed
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500 mm proximal to the growth plate and extending for 2 mm
(200 CT slices).

downstream of b-catenin are less well defined. In particular, the
precise roles of Lrp5 and Lrp6 remain controversial, despite the
compelling observations made in humans. For example mice
globally deficient for Lrp5 are born without discernable defects in
the axial or appendicular skeleton but acquire low bone mass
postnatally [14,20–22], which was attributed to a direct effect of
Lrp5 on osteoblast function. However, recent studies suggested
that the effect of Lrp5 on bone acquisition is attributable to
alterations in duodenal serotonin production [23–25], although
other studies suggest that Lrp5 acts within osteoblasts to regulate
bone mass [26,27]. By contrast, Lrp62/2 mice display defects in
both limb and axial development [9]. In addition, analysis of mice
heterozygous for a germline inactivating allele or homozygous for
a hypomorphic allele of Lrp6 have found they display lower bone
mass [7,22,28,29].
In this study, we created mouse models that permit us to clarify
the roles of Lrp5 and Lrp6 in bone during postnatal life. Our
studies indicate that expression of both Wnt co-receptors is
required within osteoblasts for normal skeletal homeostasis.

Bone Histology
Dynamic bone formation was assessed at 8 weeks of age by
injection of two sequential.25 ml doses of calcein (0.8 mg/ml)
delivered 3 and 8 days prior to sacrifice. The femur was fixed in
ethanol, dehydrated and embedded in methylmethacrylate. Three
micron sections were cut with a Microm microtome and stained
with Mason-Goldner trichrome stain. The number of osteoblasts
and osteoclasts per bone perimeter were measured at standardized
sites under the growth plate at a magnification of 200X using a
semi-automatic method (Osteoplan II, Kontron). These parameters comply with the guidelines of the nomenclature committee of
the ASBMR [34].

Osteoblast Isolation and Adenovirus Infection
Osteoblasts were isolated from calvaria of newborn Lrp5flox/flox,
Lrp6flox/flox, Lrp5flox/flox;Lrp6flox/flox, and b-cateninflox/flox mice by
serial digestion in a 1.8 mg/ml collagenase type I (Worthington
Biochemical) solution. Calvaria were digested in 10 ml of digestion
solution for 15 min at 37uC with constant agitation. The digestion
solution was collected and the digest repeated an additional 4
times. Digestion solutions 3–5, containing osteoblasts, were pooled
and cultured in a-MEM supplemented with 10% FBS and 1%
penicillin/streptomycin at 37uC in a humidified incubator
supplied with 5% CO2. To disrupt Lrp5, Lrp6, or b-catenin
expression in vitro, osteoblasts were grown to approximately 70%
confluence and then infected with control adenovirus expressing
green-fluorescent protein (ad-GFP) or adenovirus expressing Cre
recombinase (ad-CRE, Vector Biolabs) at a MOI of 100.
Osteoblasts were harvested 48 h after adenoviral infection and
deletion efficiency was assessed in a portion of the cell population
by qPCR. The remaining cells were re-plated for proliferation and
differentiation assays.

Methods
Generation of Transgenic Mice
The Institutional Animal Care and Use Committees of the
Johns Hopkins University (Animal Welfare Assurance #A327201; protocol MO11M273) and the Van Andel Research Institute
(Animal Welfare Assurance #A4383-01; protocol 10-04-015)
approved all animal procedures. Animals were monitored on a
daily basis by trained staff members of the animal care facilities
and any animals showing signs of illness or distress were humanely
euthanized to minimize suffering. Euthanasia of animals for
distress or the required timepoints was carried via inhalation of
isoflurane followed by cervical dislocation in accordance with the
recommendations of the 2000 American Veterinary Medical
Association Panel Report on Euthanasia. Lrp5flox and Lrp6flox
mice have been described previously [26,30]. To disrupt the
expression each gene in the osteoblasts, floxed mice were crossed
with Oc-Cre mice, in which cre recombinase is expressed with
high specificity and penetrance in the mature osteoblasts [31].
Genotyping strategies are available upon request. Mice were
maintained on a mixed background of C57Bl/6J, 129 and FVB/
N. b-cateninflox mice [32] were obtained from Jackson Laboratories.

Osteoblast Proliferation and Differentiation
Osteoblast proliferation was assessed by flow cytometry. Briefly,
control, DLrp5, and DLrp6 osteoblasts were cultured in a-MEM
containing 1% FBS for 48 h. BrdU (10 mM) was added to the
medium for the last 24 h before harvesting the cells. Cells were
stained with anti-BrdU-APC and 7-amino-actinomycin D and
analyzed by FACSCAlibur (BD Biosciences). Twenty thousand
events were collected for each sample and the results analyzed by
WinMDI version 2.8. For differentiation experiments, control,
DLrp5, DLrp6, DLrp5DLrp6, and Db-catenin osteoblasts were
grown to confluence and then cultured for 14 days in the presence
of 10 mM b-glycerol phosphate and 50 mg/ml ascorbic acid.
Fixed cells were stained with 1-Step NBT/BCIP (Pierce) to
examine alkaline phosphatase activity. Mineralization was assessed
using Alizarin Red (40 mM) and the von Kossa method (3%
AgNO3). Alcian Blue staining (1% solution in acetic acid) was used
to detect proteoglycan deposition.

Bone Mineral Density Analysis by DXA
Mice were anesthetized via inhalation of 2% isoflurane (TW
Medical Veterinary Supply) with oxygen (1.0 L/min) for 10 min
prior to imaging and during the procedure (# 5 min). The mice
were placed on a specimen tray in a PIXImus II bone
densitometer (GE Lunar) for analysis. Bone mineral density was
calculated by the PIXImus software based on the active bone area
in the subcranial region within the total body image.

Microcomputed Tomography (microCT)
High resolution images of the mouse femur were acquired using
a desktop microtomographic imaging system (Skyscan 1172,
Skyscan, Belgium) in accordance with the recommendations of
the American Society for Bone and Mineral Research (ASBMR)
[33]. The femur was scanned at 50 keV and 200 mA using a
0.5 mm aluminum filter with an isotropic voxel size of 10 mm. The
resulting two-dimensional cross-sectional images are shown in gray
scale. Cortical bone parameters were assessed at the femoral
midshaft and represent an average of 50 CT slices (500 mm).
Trabecular bone parameters were assessed in the distal femur
PLOS ONE | www.plosone.org

Quantitative Real-time PCR
Total RNA was extracted from bone tissue or osteoblasts grown
in vitro using the Trizol method (Invitrogen). One microgram of
pure RNA was reverse transcribed using the iScript cDNA
synthesis system (Bio-rad). Two microliters of cDNA was then
subjected to PCR amplification using iQ SYBR Green Supermix
(Bio-rad). Primer sequences were obtained from PrimerBank
(http://pga.mgh.harvard.edu/primerbank/index.html). Reactions
were normalized to endogenous b-actin reference transcript.
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skeletal tissue (ie calvaria and femur, Figure 1A). Littermates
lacking the Oc-Cre transgene (Lrp5flox/flox) served as controls.
DLrp5 mice exhibited a 55% reduction in Lrp5 expression
levels in mRNA extracted from intact femurs when compared to
control littermates (Figure 1B), and the disruption of this gene
resulted in a significant reduction in whole-body bone mineral
density (BMD) when examined by DXA at 6 months of age
(Figure 1C). The magnitude of the decrease in BMD in DLrp5
mice was similar to that reported in mice globally deficient for
Lrp5 [21,22], suggesting that the actions of Lrp5 in osteoblasts
directly regulate bone mass.
To examine the structural changes in bone that led to a
reduction in BMD in DLrp5 mice, we performed a longitudinal
analysis of bone architecture using microCT (Figure 1D–F).
Assessment of trabecular bone volume in the distal femur at both 4
and 8 weeks of age revealed that disrupting Lrp5 in the osteoblast
did not impact the attainment of peak trabecular bone volume.
However, by 16 weeks of age DLrp5 mice exhibited significant

Statistical Analysis
Results are expressed as mean 6 SEM. All statistical tests were
two-sided. A p-value less that 0.05 was considered significant.
Comparability of two groups of data was assessed using a Students
t-test.

Results
DLrp5 Mice Acquire an Osteopenic Phenotype
To begin to characterize the functions of Lrp5 and Lrp6 in bone
development, we first generated mice in which Lrp5 was
selectively disrupted in the osteoblast. Male progeny from matings
between Oc-Cre-Tg+; Lrp5flox/flox and Lrp5flox/flox [26,30] mice
with the genotype Oc-Cre-Tg+; Lrp5flox/flox (hereafter referred to
as DLrp5) were selected for detailed analysis. DLrp5 mice were
born at the expected Mendelian ratios, had a normal lifespan, and
allele specific PCR confirmed that recombination occurred only in

Figure 1. DLrp5 mice develop an osteopenic phenotype. (A) PCR analysis of Cre-mediated recombination of the Lrp5flox allele in DLrp5 mice.
Note the recombination (upper panel) is only evident in skeletal tissue. (B) qPCR analysis of Lrp5 mRNA levels in the femur of control and DLrp5 mice.
(C) Whole-bone mineral density assessed by DXA at 6months of age (n = 16–18 mice). (D) Representative microCT images of bone structure in the
distal femur of control and DLrp5 mice at 8, 16, and 24 weeks of age. (E) Quantification of trabecular bone volume per tissue volume (BV/TV) in the
distal femur. (F) Quantification of trabecular numbers (Tb.N) in the distal femur. (G) Representative microCT images of cortical bone structure at the
femoral mid-diaphysis in 24 weeks old control and DLrp5 mice. (H) Cortical tissue area (Tt.Ar). (I) Cortical bone area per tissue area (Ct.Ar/Tt.Ar). (J)
Cortical thickness (Ct. Th). (K) Polar moment of inertia (pMOI). For microCT analyses, n = 5–7mice/genotype. *p,0.05.
doi:10.1371/journal.pone.0063323.g001
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these mutants. Whereas DLrp5 mice exhibited normal trabecular bone volume until 8 weeks of age, deficiencies in trabecular
architecture were evident as early as 4 weeks of age in DLrp6
mice when compared to control littermates (Figure 3D–F).
Moreover, DLrp6 mice failed to achieve peak trabecular bone
volume and exhibited a 42% decrease in trabecular bone
volume at 8 weeks of age (Figure 3E). This phenotype was
accompanied by a profound decrease in the number of
osteoblasts and significant reductions in the mineral apposition
rate and bone formation rate (Table 2).
Cortical bone structure was also influenced by the loss of
Lrp6 function in osteoblasts (Figure 2G–K). When compared to
control littermates at 24 weeks of age, cortical tissue area and
cortical thickness were reduced by 13% and 4%, respectively, in
the DLrp6 mice. As a result, the polar moment of inertia was
reduced by 25% in the mutant mice. These data imply that
Lrp6 is required earlier in postnatal bone development than
Lrp5.

reductions in both trabecular bone volume (37%, Figure 1E) and
trabecular numbers (36%, Figure 1F). These deficiencies in
trabecular bone structure persisted through 24 weeks of age and
were accompanied by significant alterations in cortical bone
architecture (Figure 1G–K). At this time point, cortical tissue area
was reduced by approximately 20% in DLrp5 mice relative to
controls (Figure 1H), while cortical thickness was reduced by
approximately 10% (Figure 1J). As a result, the polar moment of
inertia was reduced by more than 34% in the mutant mice when
compared to controls (Figure IK).
Quantitative histomorphometry performed at the distal femur
at 8 weeks confirmed that trabecular bone volume was normal in
Lrp5 mutant (data not shown), but suggested that the bone
phenotype was beginning to develop at this time point (Table 1).
DLrp5 mice had normal numbers of osteoblasts and osteoclasts.
However, the mineralizing surface per bone surface was reduced
by more that 61% in DLrp5 mice when compared to controls and
was accompanied by a decrease in the bone formation rate and an
increase in mineralization lag time. Taken together these findings
suggest that the loss of Lrp5 function in osteoblasts can be
compensated for during the period of rapid bone growth prior to 8
weeks of age, but Lrp5 is required for proper osteoblast function
later in postnatal life.

Disrupting Lrp5 or Lrp6 Impairs Osteoblast
Differentiation in vitro
To characterize the cellular basis for the disturbances in bone
development observed in the mutant mice, we examined the
expression of each Wnt co-receptor during the differentiation of
primary osteoblasts. Lrp5 and Lrp6 mRNA were both expressed
in osteoblasts but the relative levels varied during the course of
differentiation. Lrp5 mRNA expression increased during the
differentiation process such that Lrp5 mRNA levels at day 14
were 53% higher than at day 0 (Figure 3A). By contrast, the
expression of Lrp6 remained stable during the first 7 days of
differentiation, but increased by approximately 40% at day 14
(Figure 4A).
We next tested the effect of selectively disrupting each of the coreceptors on osteoblast performance in vitro. Calvarial osteoblasts
were isolated from the floxed mice and adenoviral-Cre was
introduced to disrupt the Lrp genes. Disrupting the expression of
Lrp5 had no effect on Lrp6 mRNA (Figure 3B), but significantly
decreased Wnt3a-induced expression of Axin2 (Figure 3C),
indicating the requirement for Lrp5 in canonical Wnt signaling.
Osteoblasts deficient for Lrp5 proliferated normally (Figure 3D),
expressed alkaline phosphatase (Figure 3G) and exhibited only
minimal alterations in the expression of markers of osteoblast
differentiation (Figure 3E and 3F). However, matrix mineralization, assessed by Alizarin red and von Kossa staining, was
markedly impaired relative to controls (Figure 3G).
Disruption of Lrp6 in primary osteoblasts (Figure 4B) also
impaired Wnt signaling as indexed by reduced Wnt3a-induced
Axin2 expression (Figure 4C). The loss of Lrp6 resulted in a more
profound defect in osteoblast differentiation, even though these
cells expressed markedly increased levels of Lrp5 mRNA
(Figure 4B). Lrp6-deficient osteoblasts proliferated normally
(Figure 4D), but markers of differentiation including the expression
of Runx2, Osterix and Osteocalcin were all decreased by
approximately 30% in 14 day cultures (Figure 4E). These changes
in gene expression were accompanied by profound decreases in
alkaline phosphatase staining and mineralized nodule formation
(Figure 4G). Notably, the expression of OPG was reduced by
nearly 50% (Figure 4F) in accordance with previous studies that
demonstrate regulation of OPG by Wnt-induced b-catenin
signaling [18,19]. Taken together, these in vitro data suggest that
Lrp5 and Lrp6 function at distinct times during osteoblast
differentiation.

DLrp6 Mice Fail to Accumulate Trabecular Bone
Using an approach identical to that employed to examine Lrp5
function, we next generated mice in which Lrp6 was selectively
disrupted in the osteoblast. Oc-Cre-Tg+; Lrp6flox/flox (hereafter
referred to as DLrp6) mice were born at the expected Mendelian
ratios, had a normal lifespan, and PCR confirmed that recombination occurred only in bone (Figure 2A) and resulted in a
significant reduction in Lrp6 mRNA (56%, Figure 2B).
Much like the genetic ablation of Lrp5, disruption of Lrp6 in
osteoblasts resulted in a significant reduction in whole-body
BMD when examined by DXA at 6 months of age (Figure 2C),
but deficiencies in bone structure were evident much earlier in
Table 1. Bone histomorphometry.

Bone parameter

Control

DLrp5

Bone formation
Osteoblast number/bone perimeter
(NOb/BPm; no./100 mm)

267.606104.06 175.68629.54

Osteoid surface/bone surface (OS/BS; %)

6.7661.61

5.1260.55

Osteoid thickness (O.Th; mm)

1.7560.18

1.9860.15

290.96626.08

296.50625.76

Erosion surface/bone surface (ES/BS; %)

7.2060.37

7.7161.12

Erosion Depth (EDE, mm)

5.3660.34

6.1760.55

Bone Erosion
Osteoclast number/bone perimeter
(NOc/BPm; no./100 mm)

Bone Dynamics
Mineral apposition rate (MAR; mm/day)

3.1660.17

2.8460.18

Mineralizing surface/bone surface
(MS/BS; %)

13.7161.84

5.2660.39*

Bone formation rate/bone surface
(BFR/BS; mm3/cm2/yr)

15.5561.85

5.4660.56*

Mineralization lag time (Mlt; day)

0.3260.06

0.8860.14*

Values are shown as mean 6 S.E. (n = 5–6 per genotype at 8 weeks of age).
*p,0.05.
doi:10.1371/journal.pone.0063323.t001
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Figure 2. Trabecular and cortical bone acquisition is reduced in DLrp6 mice. (A) PCR analysis of Cre-mediated recombination of the Lrp6flox
allele in DLrp6 mice. (B) qPCR analysis of Lrp6 mRNA levels in the femur of control and DLrp6 mice. (C) Whole-bone mineral density assessed by DXA
at 6months of age (n = 16–26 mice). (D) Representative microCT images of bone structure in the distal femur of control and DLrp6 mice at 8, 16, and
24 weeks of age. (E) Quantification of trabecular bone volume per tissue volume (BV/TV) in the distal femur. (F) Quantification of trabecular numbers
(Tb.N) in the distal femur. (G) Representative microCT images of cortical bone structure at the femoral mid-diaphysis in 24 weeks old control and
DLrp6 mice. (H) Cortical tissue area (Tt.Ar). (I) Cortical bone area per tissue area (Ct.Ar/Tt.Ar). (J) Cortical thickness (Ct. Th). (K) Polar moment of inertia
(pMOI). For microCT analyses, n = 5–8mice/genotype. *p,0.05.
doi:10.1371/journal.pone.0063323.g002

demonstrated greatly impaired differentiation as assessed by
reductions in alkaline phosphatase staining (Figure 5F). Moreover,
a significant portion of cells in the 14-day cultures stained
positively for Alcian Blue and exhibited morphological and other
features compatible with chondrocytes (Figure 5G), including
increased expression of the chondrocyte differentiation markers
Sox9, Collagen II, Collagen X and Aggrecan (Figure 5H). A
similar effect was observed in primary calvarial cells lacking bcatenin. Thus the combined loss of both Lrp5 and Lrp6 in
osteoblasts appears to diminish or eliminate Wnt signaling which
in turn diverts the allocation of cells from the osteoblast to
chondrocyte lineage.

Osteoblast Lrp5/Lrp6 Double Mutants Develop Severe
Osteopenia
To explore the possibility of functional redundancy of Lrp5 and
Lrp6 in bone acquisition, we analyzed mice that lacked both Lrp5
and Lrp6 in osteoblasts (DLrp5/DLrp6) by crossing the two
individual mutants. Double mutant mice were born at the
expected Mendelian frequency but less than 50% survived beyond
7 weeks of age and fewer than 10% survived beyond 14 weeks.
Examination of bones from 4 week old animals indicated severe
loss of both trabecular and cortical bone (Figure 5A and 5B), a
phenotype indistinguishable from that observed in mice lacking bcatenin in the osteoblast [18]. At this time point, osteoblasts
numbers were reduced by more that 66%, while the number of
osteoclasts was reduced by 45% (Figure 5C and 5D).
Finally, we determined the impact of disrupting both Lrp5 and
Lrp6 in primary osteoblasts (Figure 5E). Osteoblasts lacking both
Wnt co-receptors proliferated normally (data not shown), but
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Recent studies have documented the importance of canonical
Wnt signaling in skeletal development and postnatal bone
acquisition [18,19]. However, the precise sequence of molecular
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Figure 3. Lrp5 acts in the late stages of osteoblast differentiation. (A) Lrp5 mRNA levels in primary calvarial osteoblasts were assessed by
qPCR during 14 days of osteogenic differentiation. (B) Lrp5 and Lrp6 mRNA levels were assessed by qPCR in calvarial osteoblasts isolated from Lrp5
floxed mice and infected with adenovirus expressing GFP (control) or Cre recombinase. (C) Axin2 mRNA levels were examined in control and DLrp5
osteoblasts in cells treated with 100 ng/ml Wnt-3a. (D) Cell proliferation was assessed by BrdU incorporation. Osteogenic (E) and osteoclastogenic
markers (F) were examined by qPCR after 14 days of differentiation in osteogenic media. (G) Mineralized nodule formation was assessed by staining
for alkaline phosphatase (AP), von Kossa (VK) and Alizarin red (ARS) after 14 days of differentiation. *p,0.05.
doi:10.1371/journal.pone.0063323.g003

up- and downstream of b-catenin are still unclear. In particular,
the relative contribution of the Wnt co-receptors Lrp5 and Lrp6 to
canonical Wnt signaling in bone has been controversial, in part
because of differences in the experimental models used to study
this pathway [13,14,21–24]. Here we used a genetic approach in
mice, which enabled us to unequivocally determine the impact of
disruption of Lrp5 and Lrp6 in osteoblasts during postnatal bone
acquisition. Our results demonstrate that both co-receptors are
required for normal postnatal bone acquisition, but suggest that
Lrp5 and Lrp6 exert selective actions in the osteoblast.
At birth and through 8 weeks of age, DLrp5 mice were grossly
normal and had no observable alterations in bone structure. These
findings accord with observations made in mice globally deficient
for Lrp5, which have normal bone mass at birth [14], and indicate
that the skeletal defects in mammals with Lrp5 dysfunction
manifest primarily during the postnatal period. The notion that
bone abnormalities are an acquired consequence of Lrp5
dysfunction was also suggested by Yadav et al [23,24], who
attributed the loss of bone mass in Lrp5 null mice to alterations in
serotonin production by the intestine. In this study, osteoblastspecific disruption of Lrp5 as a result of Cre expression driven by
the type I collagen promoter did not alter vertebral trabecular
bone volume, bone formation rate, osteoblast numbers, or the
expression of genes associated with osteoblast differentiation. The
discrepancy between our results and those reported by Yadav
[23,24], could be the result of differences in genetic background,
the skeletal site examined, or the time at which bone structure was
examined. Indeed, our data suggest that the bone phenotype in
DLrp5 mice is just beginning to develop at 8 weeks of age, as

events that control signaling activity through this pathway both
Table 2. Bone histomorphometry.

Bone parameter

Control

DLrp6

Bone formation
Osteoblast number/bone perimeter
(NOb/BPm; no./100 mm)

1383.946332.58 496.77681.65*

Osteoid surface/bone surface (OS/BS; %) 20.9664.10

10.5961.77*

Osteoid thickness (O.Th; mm)

1.6960.25

1.4660.24

277.42674.09

245.63656.25

Erosion surface/bone surface
(ES/BS; %)

6.2861.02

5.3861.01

Erosion Depth (EDE, mm)

5.1260.39

6.1760.39

Bone Erosion
Osteoclast number/bone perimeter
(NOc/BPm; no./100 mm)

Bone Dynamics
Mineral apposition rate (MAR; mm/day)

3.6760.26

2.9760.14*

Mineralizing surface/bone surface
(MS/BS; %)

23.8565.31

13.2162.02

Bone formation rate/bone surface
(BFR/BS; mm3/cm2/yr)

27.5765.12

14.2962.09*

Mineralization lag time (Mlt; day)

0.4360.13

0.5360.15

Values are shown as mean 6 S.E. (n = 5–6 per genotype at 8 weeks of age).
*p,0.05.
doi:10.1371/journal.pone.0063323.t002
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Figure 4. Loss of Lrp6 impairs osteoblast differentiation. (A) Lrp6 mRNA levels in primary calvarial osteoblasts were assessed by qPCR during
14 days of osteogenic differentiation. (B) Lrp6 and Lrp5 mRNA levels were assessed by qPCR in calvarial osteoblasts isolated from Lrp6 floxed mice
and infected with adenovirus expressing GFP (control) or Cre recombinase. (C) Axin2 mRNA levels were examined in control and DLrp6 osteoblasts in
cells treated with 100 ng/ml Wnt-3a. (D) Cell proliferation was assessed by BrdU incorporation. Osteogenic (E) and osteoclastogenic markers (F) were
examined by qPCR after 14 days of differentiation in osteogenic media. (G) Mineralized nodule formation was assessed by staining for alkaline
phosphatase (AP), von Kossa (VK) and Alizarin red (ARS) after 14 days of differentiation. *p,0.05.
doi:10.1371/journal.pone.0063323.g004

parameters of mineralization (MS/BS, BFR/BS and MLT) were
significantly altered but microCT and histological analyses
revealed trabecular bone volume to be normal.
The developmental abnormalities and skeletal defects in mice
globally deficient in Lrp6 are more severe than those of Lrp5
mutants; Lrp6 mutants die in the immediate postnatal period with
loss of distal limb structures and truncation of the axial skeleton
[9]. This suggests that Lrp6 may function to a greater degree
during embryogenesis and likely impacts skeletal development at
earlier stages. In agreement with this idea, primary osteoblasts
lacking Lrp6 exhibited a more profound defect in differentiation
than those lacking Lrp5. Moreover, the DLrp6 mice demonstrated
reductions in trabecular bone volume as early as 4 weeks of age
and did not achieve peak bone volume. Together these data
suggest that Lrp5 and Lrp6 function to control Wnt/b-catenin
activity over different windows of time during skeletal development. Additional studies to determine the effect of deleting each of
these co-receptors at selected times and in different osteoblast
lineages would be required to test this idea more definitively.
A noteworthy finding from our study was the observation that
both Lrp5 and Lrp6 in osteoblasts influenced cortical bone
architecture. DLrp5 mice exhibit the alterations in tissue crosssectional area that have also been reported in Lrp5 null mice [21]
and the effect of manipulating this co-receptor appeared to be
more severe than the effect of disrupting Lrp6. Since the
trabecular bone phenotype was more severe in DLrp6 mice, these
data suggest that relative importance of Lrp5 and Lrp6 may differ
across bone envelopes. Nonetheless, our data indicates a need to
PLOS ONE | www.plosone.org

explore the roles of Lrp6 as well as Lrp5 in skeletal mechanotransduction [21,35].
Despite differences in genetic background, histomorphometric
measurements and the results of our in vitro studies provide a
mechanistic explanation for the differences observed in the two
mutants. DLrp5 mice had normal numbers of osteoblasts but
exhibited reduced bone formation rates and increased mineralization lag times. Likewise, primary osteoblasts lacking Lrp5 were
able to produce alkaline phosphatase at levels similar to controls
but failed to form mineralized nodules normally. These defects in
mineralization together with the pattern of Lrp5 expression during
osteoblast differentiation in vitro suggest that this Wnt co-receptor
functions in the late stages of osteoblast differentiation. The loss of
Lrp5 function during this stage of osteoblast differentiation could
more easily be compensated for during early postnatal skeletal
development when the numbers of osteoblasts are high. Osteoblasts deficient for Lrp6 differentiated poorly in vitro, producing
lower levels of alkaline phosphatase and exhibiting reduced levels
of osteogenic gene expression, and DLrp6 mice exhibited
dramatically reduced numbers of osteoblasts. These data indicate
a defect early in the differentiation process of the osteoblast.
Considering the marked reduction in matrix mineralization in
Lrp6 deficient osteoblasts in vitro and reduced numbers of
osteoblasts in vivo, we were surprised that dynamic measures of
osteoblast activity including mineral apposition rates and mineralization lag time were not affected to a greater degree in DLrp6
mice. This observation may result from the marked up-regulation
of Lrp5 mRNA following the deletion of Lrp6. Consistent with this
7
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Figure 5. DLrp5/Lrp6 double mutants exhibit severe bone loss. Representative microCT images from the proximal tibia (A) and femoral
midshaft (B) are shown for 4 week old control and OBDLrp6/DLrp6 mice. (C) Osteoblasts numbers per bone perimeter (Ob.N/BPM) and (D) Osteoclasts
numbers per bone perimeter (Oc.N/BPM) were quantified in the distal femur of 4 week old mice. (E) Lrp5 and Lrp6 mRNA levels were assessed by
qPCR in calvarial osteoblasts isolated from Lrp5/Lrp6 floxed mice and infected with adenovirus espressing GFP (control) or Cre recombinase. (F)
Osteogenic differentiation was assessed by staining for alkaline phosphatase after 14 days. Alcian blue staining (G) and qPCR (H) were used to identify
cells with a chondrocyte-like phenotype in cultures of control, DLrp5/DLrp6, and Db-catenin calvarial cells grown under osteogenic conditions.
doi:10.1371/journal.pone.0063323.g005

Despite the differences in the skeletal phenotypes in DLrp5 and
DLrp6 mice, it is evident that the Wnt co-receptors exert
overlapping functions. Wnt-3a-induced expression of Axin2 was
diminished but not abolished by the disruption of either Wnt coreceptor and only disrupting both Lrp5 and Lrp6 in osteoblasts
produced a bone phenotype reminiscent of that observed in mice
lacking b-catenin in these cells [18]. These double mutants
exhibited severely reduced trabecular and cortical bone and less
than 10% survived beyond 14 weeks of age. Osteoblasts lacking
both Lrp5 and Lrp6 demonstrated greatly impaired osteoblast
differentiation and attained a chondrocyte like phenotype in
agreement with previous studies in osteoblasts lacking b-catenin
[37]. Thus, the combined loss of both Lrp5 and Lrp6 in osteoblasts

idea, mice expressing a mutant Lrp5 receptor that enhances Wnt
signaling in osteoblasts display dramatically increased parameters
of mineralization [36].
The more dramatic effect of Lrp6 loss of function on bone
volume may also be related to the influence of osteoblasts on
osteoclast development. Lrp6 deficient osteoblasts expressed lower
levels of OPG, which is consistent with the notion that canonical
Wnt signaling regulates the coupling of osteoblasts and osteoclasts
[19]. That the numbers of osteoclasts in DLrp6 were comparable
to those in controls, must be viewed in the context of the dramatic
reduction in osteoblasts in the mutants. In this regard the ratio of
osteoclasts to osteoblasts would be much higher in the mutant
mice than in the controls.
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appears to be required to fully eliminate Wnt signaling and in turn
divert the allocation of cells from the osteoblast to chondrocyte
lineage. This is consistent with the deficiency in commitment to
the osteoblast lineage seen in embryos in which Lrp5 and Lrp6
were deleted from osteochondral progenitors using Dermo1-cre
[26].
In summary, our studies demonstrate that the highly related
Wnt co-receptors Lrp5 and Lrp6 are expressed in osteoblasts and
are both required for normal postnatal bone acquisition in mice.
We conclude that the activities of these co-receptors regulate
canonical Wnt signaling in osteoblasts over different windows of
time and in different skeletal compartments to promote proper
acquisition of both cortical and trabecular bone.
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